11
Participants
Start Date
April 7, 2021
Primary Completion Date
May 14, 2024
Study Completion Date
May 14, 2024
PQ Bypass System
Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.
Sentara Norfolk, Norfolk
AMITA Medical Group, Elk Grove Village
The Vascular Experts, Old Saybrook
Lead Sponsor
Endologix
INDUSTRY